InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,667.20
(
0.64%
)
US TECH 100
19,846.80
(
0.00%
)
Dow Jones
40,954.48
(
1.85%
)
Brent Oil
83.32
(
-1.22%
)
Bitcoin
64,471.58
(
-0.59%
)
Post# of 252611
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120056
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 179844

Wednesday, 09/24/2014 12:02:20 PM

Wednesday, September 24, 2014 12:02:20 PM

Post# of 252611
GILD submits Japan NDA for Sovaldi + Ledipasvir combination in GT1 patients:

http://finance.yahoo.com/news/gilead-submits-drug-application-japan-040000790.html

Unlike the US and EU submissions for Sovaldi + Ledipasvir, the proposed duration of treatment is 12 weeks for all subgroups.

GILD submitted a Japan NDA for Sovaldi + ribavirin in GT2 patients in Jun 2014 (#msg-103797270). GT1b and GT2 comprise the overwhelming majority of HCV patients in Japan.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up